Project Grant R01AG092462

Award Date 6/1/25
Completion Date 3/31/30
Dollars Obligated $718K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
This $1,592,854 project grant was awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Illinois to investigate the molecular mechanisms underlying tau protein dysfunction in neurodegenerative tauopathies, including Alzheimer's disease and related dementias. The overarching goal is to understand how disease-related changes in tau conformation and post-translational modifications disrupt tau's normal scaffolding functions and lead to dysregulation of key...
This federal Project Grant award of $1,118,700.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to New York University School of Medicine will support research to elucidate the role of pathological tau protein in disrupting endosomal microautophagy (EMI), a critical protein degradation pathway affected in Alzheimer's disease. The research aims to determine which components of the EMI pathway are most vulnerable to tau pathology and whether restoring EMI function can...
This federal Project Grant award of $816,661 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a research initiative by the Regents of the University of California, San Francisco (UCSF) to comprehensively map the impact of tau pathology on the proteome, which is expected to be mediated in part through disruptions in mRNA splicing. The research leverages AD mouse models and human iPSC tauopathy models to discover protein drivers of tauopathy and validate such drivers in...
The National Institute on Aging (NIA) awarded a $773,816 Project Grant (CFDA 93.866 - Aging Research) to the University of California, Irvine to conduct a comprehensive study on the molecular mechanisms underlying aberrant protein accumulation in Alzheimer's disease-related tauopathies. The project aims to generate cell-type-specific atlases of misprocessed RNAs and proteins in mouse models and human brain tissues to identify new pathways and protein interaction networks involved in...
This $459,076 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will support research into the early transcriptional and pathological changes in vulnerable brain regions during the prodromal stage of Alzheimer's disease (AD). The project will leverage single-nucleus RNA sequencing and targeted mass spectrometry analysis of postmortem brain samples from individuals with early-stage AD pathology to profile gene expression changes and identify...
This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $784,596 to Northeastern University to conduct comprehensive and cell type-specific proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The 5-year project aims to improve understanding of AD's causes, identify new therapeutic targets, and develop new tools for studying protein dysfunctions in AD. Key objectives include applying...
This $1,100,000 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports research by the University of Texas Medical Branch at Galveston (UTMB) to investigate the mechanisms of pathological tau protein spreading in Alzheimer's disease. The project aims to determine how amyloid-beta oligomers modulate the binding and internalization of toxic tau oligomers at synapses, which is a key component of the trans-synaptic spreading of tau...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research into the role of local protein synthesis in the development of tau pathology and neurodegeneration associated with Alzheimer's disease. The $1,147,300 grant awarded to Wayne State University will fund a 5-year project to investigate how pathogenic forms of the tau protein interfere with dendritic protein synthesis, which may contribute to the early synaptic dysfunction seen in...

This $717,709 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Weill Medical College of Cornell University aims to discover Alzheimer's disease (AD)-relevant cellular mechanisms underlying the propagation of misfolded tau aggregates in human neurons. The research will utilize advanced proteomic techniques, including affinity purification mass spectrometry and transcriptomics, in combination with newly generated knockin human induced pluripotent stem cell (iPSC) models expressing different tau isoforms. The study has three specific objectives: 1) determine tau interactomes influenced by amyloid-beta and tau seeding in different tau isoforms, 2) investigate the role of the VPS29 protein in tau aggregation and its impact on proteomic and transcriptomic profiles, and 3) explore how the ufmylation pathway regulates tau aggregation and its interactions with the retromer pathway. The findings from this research are expected to provide unprecedented insights into AD-related tau pathology and inform the development of novel therapeutic strategies.

Generated 6/17/25, 2:42 AM